HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Chronic residual schizophrenia — Clinical Guidelines

Overview

Chronic residual schizophrenia refers to a persistent state of the illness characterized by ongoing symptoms despite treatment. This phase emphasizes the need for continuous management to optimize functioning and prevent relapse.

Diagnosis

No information provided in the abstracts.

Management

Second-generation antipsychotic agents should be used continuously for 2-5 years 4.

Long-acting injectable (LAI) antipsychotics are primarily used for relapse prevention and may be useful for acute treatment in some situations 1.

LAIs are not significantly different in efficacy for overall symptoms compared to oral formulations 1.

Some side effects may be less frequent with LAIs compared to oral counterparts 1.

LAI use is associated with a small, but significant, increased odds of any infection versus placebo 2.

Early treatment of comorbid substance use is recommended 4.

Special Populations

No information provided in the abstracts.

Key Recommendations

Comprehensive treatment should utilize second-generation antipsychotic agents continuously for 2-5 years (Evidence: Expert opinion) 4.

Continuous funding is needed for clinical services focusing on early detection, treatment, and recovery to proactively implement guidelines (Evidence: Expert opinion) 4.

General practitioners have an important role in monitoring and reducing high cardiovascular risk in this population (Evidence: Expert opinion) 4.

References

1 Wang D, Schneider-Thoma J, Siafis S, Qin M, Wu H, Zhu Y et al.. Efficacy, acceptability and side-effects of oral versus long-acting- injectables antipsychotics: Systematic review and network meta-analysis. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2024. link 2 Malham KM, Miller BJ. Long-Acting Injectable Antipsychotics and Infections in Schizophrenia. Journal of clinical psychopharmacology 2023. link 3 Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. The lancet. Psychiatry 2021. link00039-0) 4 Castle DJ, Galletly CA, Dark F, Humberstone V, Morgan VA, Killackey E et al.. The 2016 Royal Australian and New Zealand College of Psychiatrists guidelines for the management of schizophrenia and related disorders. The Medical journal of Australia 2017. link

Chronic residual schizophrenia